Drug profile · INN
cabozantinib
CABOMETYX
cabozantinib (CABOMETYX) is a hepatocyte growth factor receptor inhibitor. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
Drug details — cabozantinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 8
- Programs
- 15
- Data quality
- 0.89
Quick answer
cabozantinib (CABOMETYX) is a hepatocyte growth factor receptor inhibitor. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hepatocyte growth factor receptor inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12410170
2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds
granted -
US 12384773
Thiazole compounds and methods of use thereof
granted -
US 11993584
Solid forms of an azolopyrimidine compound
granted -
US 11667662
Modulators of 5′-nucleotidase, ecto and the use thereof
granted -
US 11478479
Dosing with an azolopyrimidine compound
granted -
US 11001603
Modulators of 5′-nucleotidase, ecto and the use thereof
granted -
US 10981944
Modulators of 5′-nucleotidase, ecto and the use thereof
granted -
US 10239912
Modulators of 5′-nucleotidase, ecto and the use thereof
granted
Frequently asked questions
What is cabozantinib?
cabozantinib (CABOMETYX) is a hepatocyte growth factor receptor inhibitor. Associated with Ipsen. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cabozantinib?
CABOMETYX is a marketed brand name for cabozantinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cabozantinib?
cabozantinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.